- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Interstitial lung disease associated with systemic sclerosis (SSc-ILD) ; volume:20 ; number:1 ; day:18 ; month:1 ; year:2019 ; pages:1-10 ; date:12.2019
Respiratory research ; 20, Heft 1 (18.1.2019), 1-10, 12.2019
- Urheber
-
Cottin, Vincent
Brown, Kevin K.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-019-0980-7
- URN
-
urn:nbn:de:101:1-2019022022080056189134
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cottin, Vincent
- Brown, Kevin K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Pathogenesis of interstitial lung disease in systemic sclerosis
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?
Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease
Extracellular vesicles and interstitial lung disease in systemic sclerosis: State of the art!
CD19 + CD21lo/neg cells are increased in systemic sclerosis-associated interstitial lung disease
Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases
Circulating cytokine levels in systemic sclerosis related interstitial lung disease and idiopathic pulmonary fibrosis
Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Pathogenesis of interstitial lung disease in systemic sclerosis
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?
Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease
Extracellular vesicles and interstitial lung disease in systemic sclerosis: State of the art!
CD19 + CD21lo/neg cells are increased in systemic sclerosis-associated interstitial lung disease
Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases
Circulating cytokine levels in systemic sclerosis related interstitial lung disease and idiopathic pulmonary fibrosis
Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Pathogenesis of interstitial lung disease in systemic sclerosis
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?
Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease
Extracellular vesicles and interstitial lung disease in systemic sclerosis: State of the art!
CD19 + CD21lo/neg cells are increased in systemic sclerosis-associated interstitial lung disease
Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases